A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Trial Profile

A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Neratinib (Primary) ; Temsirolimus (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Puma Biotechnology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 11 May 2016 This trial was completed in Spain according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top